Adell Harriman & Carpenter Inc. Invests $413,000 in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Adell Harriman & Carpenter Inc. acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 999 shares of the company’s stock, valued at approximately $413,000.

A number of other institutional investors also recently added to or reduced their stakes in the business. V Square Quantitative Management LLC lifted its holdings in IDEXX Laboratories by 6.2% in the fourth quarter. V Square Quantitative Management LLC now owns 2,076 shares of the company’s stock valued at $858,000 after acquiring an additional 121 shares during the period. CFC Planning Co LLC purchased a new position in shares of IDEXX Laboratories in the 4th quarter valued at about $487,000. Vontobel Holding Ltd. lifted its stake in shares of IDEXX Laboratories by 90.1% in the fourth quarter. Vontobel Holding Ltd. now owns 418,563 shares of the company’s stock valued at $173,051,000 after purchasing an additional 198,404 shares during the period. Asset Management One Co. Ltd. boosted its holdings in IDEXX Laboratories by 6.1% during the fourth quarter. Asset Management One Co. Ltd. now owns 52,844 shares of the company’s stock worth $21,927,000 after buying an additional 3,057 shares in the last quarter. Finally, Avestar Capital LLC grew its position in IDEXX Laboratories by 5.9% during the fourth quarter. Avestar Capital LLC now owns 804 shares of the company’s stock worth $332,000 after buying an additional 45 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

IDXX has been the subject of several research reports. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Leerink Partners started coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They set an “outperform” rating and a $500.00 price target for the company. Barclays boosted their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Piper Sandler raised their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Finally, StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, February 5th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $533.75.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now owns 3,061 shares of the company’s stock, valued at $1,426,242.34. The trade was a 49.50 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the transaction, the director now owns 905 shares in the company, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 13,330 shares of company stock valued at $6,161,276. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Price Performance

NASDAQ IDXX opened at $444.53 on Friday. The company has a 50-day moving average price of $430.77 and a two-hundred day moving average price of $453.31. The stock has a market cap of $36.40 billion, a price-to-earnings ratio of 41.66, a price-to-earnings-growth ratio of 3.47 and a beta of 1.37. The company has a current ratio of 1.31, a quick ratio of 1.03 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $583.39.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.